Artivion, Inc. (NYSE:AORT) Receives $51.00 Consensus PT from Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $51.00.

Several equities analysts recently issued reports on the company. Canaccord Genuity Group reduced their price target on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a research report on Friday, April 10th. Needham & Company LLC restated a “buy” rating on shares of Artivion in a research report on Monday, April 20th. Stifel Nicolaus set a $55.00 price target on Artivion in a research report on Thursday, March 5th. Finally, Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research report on Saturday.

Artivion Stock Performance

Shares of NYSE AORT opened at $36.34 on Wednesday. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 181.71 and a beta of 1.63. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. Artivion has a 1-year low of $23.04 and a 1-year high of $48.25. The stock’s 50-day moving average is $36.70 and its 200 day moving average is $41.40.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion’s quarterly revenue was up 19.2% on a year-over-year basis. On average, sell-side analysts anticipate that Artivion will post 0.63 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Lance A. Berry sold 6,316 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $238,618.48. Following the transaction, the executive vice president directly owned 210,827 shares in the company, valued at $7,965,044.06. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 8,962 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total value of $340,556.00. Following the transaction, the senior vice president owned 185,095 shares in the company, valued at approximately $7,033,610. The trade was a 4.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 133,043 shares of company stock valued at $4,977,158 in the last 90 days. 6.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Artivion

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its position in shares of Artivion by 578.4% in the 4th quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock worth $1,780,000 after buying an additional 33,277 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Artivion in the 2nd quarter worth approximately $664,000. JPMorgan Chase & Co. grew its position in shares of Artivion by 338.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after buying an additional 94,312 shares during the last quarter. Public Sector Pension Investment Board grew its position in shares of Artivion by 23.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock worth $6,858,000 after buying an additional 30,989 shares during the last quarter. Finally, Champlain Investment Partners LLC bought a new stake in shares of Artivion in the 3rd quarter worth approximately $17,912,000. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.